Global Medical Debate Erupts Over Proposed 'Preclinical Obesity' Diagnosis Beyond BMI

A Lancet Diabetes and Endocrinology global commission has proposed dividing obesity into two distinct categories — preclinical and clinical — sparking intense debate among medical experts worldwide.

The Proposal

The commission, which published its framework over a year ago, argues for redefining obesity using a new diagnostic hierarchy:

1. Preclinical obesity: Excess body fat with risk of, but no current diagnosis of, cardiovascular problems, type 2 diabetes, cancers, or organ dysfunction
2. Clinical obesity: Excess body fat with already-developed chronic illness

Why BMI Is Being Challenged

Critics have long argued that Body Mass Index is fundamentally flawed:

• Groups muscular individuals with obese individuals
• Ignores population differences (ethnicity, age, gender)
• Doesn't distinguish between fat mass and lean mass
• Says nothing about fat distribution (visceral vs. subcutaneous)

New Metrics Proposed

The commission recommends replacing BMI-centric diagnosis with:

• Waist circumference
• Waist-to-hip ratio
• Waist-to-height ratio
• Body fat percentage measurements

Implications

• Drug prescribing: Preclinical patients may benefit from early GLP-1 intervention
• Insurance coverage: New diagnostic categories could expand or limit treatment access
• Clinical trials: Different endpoints needed for preclinical vs. clinical populations
• Global health policy: WHO may need to update obesity classification

Industry Impact

With the GLP-1 obesity drug market projected to exceed $100 billion by 2030, diagnostic precision directly affects market sizing and prescribing patterns.